Last updated: July 26, 2026
What is the docket and court posture for Valeant International (Barbados) SRL v. Paddock Laboratories, Inc. | 0:10-cv-01571?
The matter is a federal patent infringement case filed in 2010 and docketed as 0:10-cv-01571 against Paddock Laboratories, Inc. by Valeant International (Barbados) SRL. The action is assessed as a generic-competition IP dispute rather than a regulatory merits case because the parties’ relationship and typical Valeant v. generic fact patterns point to Orange Book-driven patent assertions and infringement allegations tied to an abbreviated or market-approaching product.
What patents did Valeant assert in Valeant v. Paddock (0:10-cv-01571)?
No patent numbers, asserted claims, or asserted patent titles are provided in the input. Without the complaint, amended complaint, or the docket’s infringement content, a complete and accurate identification of the asserted patent estate cannot be produced.
What product and mechanism were at issue in Valeant v. Paddock (0:10-cv-01571)?
No drug name, NDA/ANDA number, dosage form, or active ingredient is provided in the input. Patent litigation outcomes, exclusivity posture, and generic-entry timelines all depend on the specific product and the market device (NDA vs ANDA; NDA Orange Book patents vs non-Orange Book claims). That data is not present.
What are the key procedural events and milestones in 0:10-cv-01571?
The input does not include PACER docket entries, scheduling orders, claim construction dates, trial dates, or motion outcomes. A litigation “summary and analysis” at docket level requires: complaint date, responsive pleading date, preliminary injunction posture, Markman (if any), summary judgment rulings, settlement or dismissal date, and the final disposition.
Did Valeant seek an injunction and what happened to it?
No information is included about a preliminary injunction request, the court’s decision, or the status of any injunction motion. Injunction disposition is often the practical driver of immediate market exclusion risk, but cannot be reconstructed from the provided prompt.
How does Valeant v. Paddock fit into the Hatch-Waxman framework (Paragraph IV, declaratory judgments, and Orange Book listings)?
The input provides no NDA/ANDA context, no Orange Book patent listing reference, and no Paragraph IV or counterclaim details. As a result, Paragraph IV posture and FDA submission linkage cannot be stated.
What is the legal theory (infringement, induced infringement, contributory infringement) for 0:10-cv-01571?
No complaint allegations or infringement theory are provided. Without the complaint or the claim chart content, it is not possible to accurately describe whether Valeant asserted direct infringement only, induced infringement, contributory infringement, willfulness, or inducement based on labeling or instructions for use.
What defenses did Paddock raise (noninfringement, invalidity, unenforceability, statute, lack of standing)?
No responsive pleading or motion record is included. Litigation analysis requires at least: invalidity grounds (anticipation/obviousness), unenforceability bases (inequitable conduct or prosecution history), claim construction positions, and any jurisdiction or standing arguments.
What claim construction or technology issues mattered most?
No claim terms, construction orders, or technical manufacturing/formulation facts are provided. Claim scope is the hinge for infringement/noninfringement and for invalidity defenses, so this cannot be analyzed from the current input.
What does the outcome imply for generic entry risk for the relevant drug?
The input does not include a final disposition (judgment, settlement, dismissal), effective date of any launch restriction, or any consent judgment terms. Without outcome data, the generic-entry risk cannot be quantified.
Which companies are linked to 0:10-cv-01571 (manufacturing partners, ANDA holders, co-defendants)?
No co-defendants, ANDA holders, contract manufacturers, or sellers are listed in the prompt. Litigation and product risk mapping require those entities to determine who controls labeling, formulation, and distribution.
How strong is the patent estate for the asserted product based on this case?
No asserted patents, claim counts, or litigation rulings are provided. Patent strength cannot be inferred without: (i) which patents were asserted, (ii) whether they survived claim construction, (iii) validity findings or settlement economics tied to specific patents.
What settlement or licensing outcome occurred in Valeant v. Paddock (0:10-cv-01571)?
No settlement agreement terms, dismissal-with-prejudice language, or consent decree details are provided. Such terms often determine launch dates, design-around requirements, royalty/transfer payments, and covenants not to sue.
What is the Orange Book status and exclusivity expiration timeline relevant to this litigation?
No Orange Book listings, NDA/ANDA, pediatric exclusivity, marketing exclusivity, or patent expiration dates are provided. Without drug identity and patent numbers, the exclusivity timeline cannot be stated.
Key Takeaways
- The case is identified as Valeant International (Barbados) SRL v. Paddock Laboratories, Inc., 0:10-cv-01571, filed in federal court in 2010, but the provided input does not include any substantive litigation record (asserted patents, docket milestones, rulings, or disposition).
- A legally actionable litigation summary and IP/entry analysis cannot be produced without at least the asserted patent numbers and the case outcome.
FAQs
- What patents were asserted by Valeant in 0:10-cv-01571?
- Was there a Paragraph IV notice or an ANDA-linked declaratory judgment in Valeant v. Paddock?
- Did the court grant or deny a preliminary injunction in 0:10-cv-01571?
- What was the final disposition date and what did it mean for generic launch?
- Which Orange Book patents and exclusivities controlled the product tied to 0:10-cv-01571?
References
(No sources are cited because the prompt provides no docket extracts, opinions, patent lists, or Orange Book identifiers to support factual statements.)
